Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DelSiTech Ltd.
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- Drug Delivery
- Implantable Devices